masld glp 1 GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD) | Current Hepatology Reports Incretin-based therapies in MASLD/MASH: from
Description
Gotfredsen CF, Mlck A-M, Thorup I, et al
General directions for use include: Take 1 tablet once daily in the morning on an empty stomach
These can include fainting and seizures
Various alternatives and considerations If monotherapy or dual-combination therapy fails to achieve the target HbA1c levels, a combination of three or more oral antidiabetic agents may be considered
Blood testing helps pinpoint underlying deficiencies quickly
